Bayer Investors Left Hanging as Supreme Court Signals Split on Roundup Pre-emption

Supreme Court arguments on Bayer's bid to end Roundup lawsuits show divided bench; shares fall 6.5% as analysts see 70% win odds but warn of litigation risks.

The US Supreme Court’s oral arguments on Monday over Bayer’s bid to shut down state-level Roundup lawsuits ended without the decisive victory the company had banked on, sending shares sliding and leaving the legal landscape for thousands of claims hanging in the balance.

For nearly 90 minutes, the justices debated whether federal law pre-empts state failure-to-warn claims against the glyphosate-based herbicide. Bayer’s core argument is straightforward: the Environmental Protection Agency did not require a cancer warning on Roundup labels, so plaintiffs cannot sue over its absence. But the court’s questions revealed a deeply divided bench.

Justice Brett Kavanaugh appeared sympathetic to Bayer’s position, questioning whether such lawsuits undermine the federal mandate for uniform pesticide labelling. Chief Justice John Roberts pushed back, suggesting states should retain the power to alert their citizens to newly identified product risks. Justice Amy Coney Barrett gave little away, leaving analysts at Bank of America to describe the hearing as “less clearly pro-Bayer than expected.” Still, a legal expert cited by the bank pegs the company’s odds of victory at 70%.

The stakes could hardly be higher. A win for Bayer would wipe out the legal foundation for roughly 80% of the more than 100,000 outstanding Roundup cases, according to JPMorgan analysts. A loss, by contrast, would unleash a fresh wave of litigation — potentially rendering a $7.25 billion settlement announced in February insufficient to cap future claims. That deal, which received preliminary approval from a Missouri judge in March, faces a final hearing in July. Plaintiffs have until June 4 to opt in.

“Without a Supreme Court victory, the settlement does not provide reliable protection against future lawsuits,” said Markus Manns, a portfolio manager at Union Investment and a Bayer shareholder. The company has already shelled out approximately $11 billion in total Roundup-related settlement costs.

The market reaction was swift. Bayer shares lost as much as 6.5% on Monday and closed at €36.62 — roughly 25% below the 52-week high of €49.17 hit in February. The stock has now fallen 9% over the past seven days, with the 200-day moving average at €34.46 emerging as a potential technical support level.

Analysts remain split. UBS’s Matthew Weston maintains a buy rating and a €52 price target, arguing the legal overhang is already priced in. But the uncertainty is palpable, and a final ruling is not expected until late June or early July.

Beyond the courtroom, Bayer faces a busy calendar. On Wednesday, the company pays a dividend of just €0.11 per share — a stark reminder of the cost-cutting drive under CEO Bill Anderson. More importantly, first-quarter results are due on May 12, offering investors a chance to gauge progress on debt reduction and the broader restructuring plan. For now, all eyes remain fixed on the Supreme Court, where the fate of Bayer’s glyphosate legacy hangs by a thread.